{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:46:17Z","timestamp":1791866777117,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01436-y","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:49:34Z","timestamp":1787989774000},"page":"3003-3015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical Considerations Shaping Pneumococcal Vaccine Selection: A Multinational Cross-Sectional Survey of Healthcare Professionals"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-3098","authenticated-orcid":false,"given":"Jeffrey T.","family":"Vietri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"1436_CR1","unstructured":"Dion CF, Ashurst JV. Streptococcus pneumoniae. StatPearls. Treasure Island: StatPearls; 2025."},{"key":"1436_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050420","author":"C Scelfo","year":"2021","unstructured":"Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and invasive pneumococcal diseases: the role of pneumococcal conjugate vaccine in the era of multi-drug resistance. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9050420.","journal-title":"Vaccines"},{"key":"1436_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis. 2026;26(4):343\u201361.","DOI":"10.1016\/S1473-3099(25)00689-9"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2147\/IJGM.S409476","volume":"16","author":"A Al-Jumaili","year":"2023","unstructured":"Al-Jumaili A, Dawood HN, Ikram D, Al-Jabban A. Pneumococcal disease: global disease prevention strategies with a focus on the challenges in Iraq. Int J Gen Med. 2023;16:2095\u2013110.","journal-title":"Int J Gen Med"},{"key":"1436_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101197","author":"L Huang","year":"2024","unstructured":"Huang L, Li X, Eugenia N, et al. Burden of pneumococcal disease in young children due to serotypes contained in different pneumococcal conjugate vaccines in eight Asian countries and territories. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12101197.","journal-title":"Vaccines"},{"issue":"3","key":"1436_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf093","volume":"12","author":"J Li","year":"2025","unstructured":"Li J, Yung CF, Kam KQ, et al. Invasive pneumococcal disease and impact of 7- and 13-valent pneumococcal conjugate vaccines in Singapore children over 24\u00a0years. Open Forum Infect Dis. 2025;12(3):ofaf093.","journal-title":"Open Forum Infect Dis"},{"key":"1436_CR7","unstructured":"Pneumococcal Vaccine Recommendations: CDC: US Centers for Disease Control and Prevention. 2024. https:\/\/www.cdc.gov\/pneumococcal\/hcp\/vaccine-recommendations\/index.html. Accessed 18 Nov 2025"},{"key":"1436_CR8","unstructured":"Considerations for pneumococcal vaccination in older adults: WHO. 2021. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/809bd3ad-0849-4a3e-8871-1c7baa90caa8\/content. Accessed 18 Nov 2025"},{"key":"1436_CR9","unstructured":"WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5\u00a0years\u2014September 2025: WHO. 2025. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/2cce44bc-af0b-4103-9048-54353f7d7ba1\/content. Accessed 18 Nov 2025"},{"key":"1436_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/wjv.2025.151001","volume":"15","author":"Q Ekpa","year":"2003","unstructured":"Ekpa Q, Oranu K, Okobi O, Adekoya O. The evolution of pneumococcal vaccine and vaccine schedule in the USA: a narrative review of the last two decades (2003-2023). World J Vaccines. 2003;15:1\u201319.","journal-title":"World J Vaccines"},{"key":"1436_CR11","volume-title":"StatPearls","author":"S Tereziu","year":"2025","unstructured":"Tereziu S, Minter DA. Pneumococcal vaccine. In: StatPearls. Treasure Island (FL): StatPearls; 2025."},{"issue":"1","key":"1436_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41479-022-00097-y","volume":"14","author":"DM Musher","year":"2022","unstructured":"Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (Nathan). 2022;14(1):5.","journal-title":"Pneumonia (Nathan)"},{"issue":"6","key":"1436_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1513\/AnnalsATS.201401-042CME","volume":"11","author":"M Mirsaeidi","year":"2014","unstructured":"Mirsaeidi M, Schraufnagel DE. Pneumococcal vaccines: understanding centers for disease control and prevention recommendations. Ann Am Thorac Soc. 2014;11(6):980\u20135.","journal-title":"Ann Am Thorac Soc"},{"issue":"26","key":"1436_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126390","volume":"42","author":"MA Fletcher","year":"2024","unstructured":"Fletcher MA, Vojicic J, Daigle D, et al. National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific. Vaccine. 2024;42(26):126390.","journal-title":"Vaccine"},{"issue":"5","key":"1436_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050498","volume":"13","author":"L Ozisik","year":"2025","unstructured":"Ozisik L. The new era of pneumococcal vaccination in adults: what is next? Vaccines (Basel). 2025;13(5):498.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1436_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf050","volume":"12","author":"D Thindwa","year":"2025","unstructured":"Thindwa D, Shapiro ED, Weinberger DM. The complex landscape of updated pneumococcal conjugate vaccines. Open Forum Infect Dis. 2025;12(2):ofaf050.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1436_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","volume":"71","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109\u201317.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"1436_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","volume":"73","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1436_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11349-6","volume":"24","author":"W Ayenew","year":"2024","unstructured":"Ayenew W, Anagaw YK, Limenh LW, et al. Readiness of and barriers for community pharmacy professionals in providing and implementing vaccination services. BMC Health Serv Res. 2024;24(1):867.","journal-title":"BMC Health Serv Res"},{"key":"1436_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070756","author":"AH Chinchilla","year":"2025","unstructured":"Chinchilla AH, Melton TC, Westrick SC, et al. A cross-sectional survey to identify current pneumococcal vaccination practices and barriers in rural community pharmacies. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13070756.","journal-title":"Vaccines"},{"issue":"3","key":"1436_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/21645515.2018.1543524","volume":"15","author":"O Equils","year":"2019","unstructured":"Equils O, Kellogg C, Baden L, Berger W, Connolly S. Logistical and structural challenges are the major obstacles for family medicine physicians\u2019 ability to administer adult vaccines. Hum Vaccin Immunother. 2019;15(3):637\u201342.","journal-title":"Hum Vaccin Immunother"},{"key":"1436_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071164","author":"J Huang","year":"2022","unstructured":"Huang J, Mak FY, Wong YY, et al. Enabling factors, barriers, and perceptions of pneumococcal vaccination strategy implementation: a qualitative study. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10071164.","journal-title":"Vaccines"},{"issue":"1","key":"1436_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/14760584.2024.2417393","volume":"23","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Tsai J-H, Ning N, et al. Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States. Expert Rev Vaccines. 2024;23(1):966\u201373.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"1436_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40121-019-00266-5","volume":"8","author":"P Sacco","year":"2019","unstructured":"Sacco P, Myers K, Poulos C, et al. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019;8(4):657\u201370.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1436_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/14760584.2025.2585808","volume":"24","author":"J Vietri","year":"2025","unstructured":"Vietri J, Myers K, Huang L, et al. Healthcare providers\u2019 preferences for pediatric pneumococcal vaccination recommendations in the United States. Expert Rev Vaccines. 2025;24(1):1024\u201332.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"1436_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2325745","volume":"20","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Tsai JH, Ning N, et al. Understanding healthcare providers\u2019 preferred attributes of pediatric pneumococcal conjugate vaccines in the United States. Hum Vaccin Immunother. 2024;20(1):2325745.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1436_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-018-0320-2","volume":"16","author":"J Moberg","year":"2018","unstructured":"Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE evidence to decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018;16(1):45.","journal-title":"Health Res Policy Syst"},{"key":"1436_CR28","volume":"1","author":"M Beitelshees","year":"2025","unstructured":"Beitelshees M, Hill A, Rosemarino NM, Jones CH. Projecting the adult vaccine capacity gap in the United States: forecasting demand and throughput through 2035. Dis Ther. 2025;1:100003.","journal-title":"Dis Ther"},{"issue":"1","key":"1436_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00809-z","volume":"9","author":"CH Jones","year":"2024","unstructured":"Jones CH, Jenkins MP, Adam Williams B, Welch VL, True JM. Exploring the future adult vaccine landscape-crowded schedules and new dynamics. NPJ Vaccines. 2024;9(1):27.","journal-title":"NPJ Vaccines"},{"key":"1436_CR30","first-page":"264","volume-title":"Globally resilient supply chains for seasonal and pandemic influenza vaccines","year":"2022","unstructured":"Ashby E, Jefferson KMP, Yadav P, Anupindi R, editors. Globally resilient supply chains for seasonal and pandemic influenza vaccines. Washington, DC: The National Academies Press; 2022. p. 264."},{"key":"1436_CR31","doi-asserted-by":"publisher","first-page":"117863372110187","DOI":"10.1177\/11786337211018712","volume":"14","author":"A Kamineni","year":"2021","unstructured":"Kamineni A, Blasi PR, Gundersen GD, et al. Barriers to human papillomavirus vaccine series completion among insured individuals in an integrated healthcare setting. Infect Dis (Auckl). 2021;14:11786337211018712.","journal-title":"Infect Dis (Auckl)"},{"key":"1436_CR32","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v12i4.4225","author":"M Rusnack","year":"2021","unstructured":"Rusnack M. COVID vaccine transport, storage, and distribution: cold chain management to ensure efficacy. Innov Pharm. 2021. https:\/\/doi.org\/10.24926\/iip.v12i4.4225.","journal-title":"Innov Pharm"},{"key":"1436_CR33","doi-asserted-by":"crossref","unstructured":"Waheed DEN, Bolio A, Guillaume D, et al. Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: what works in the context of low-resource countries? Front Pub Health. 2023;11:1112981.","DOI":"10.3389\/fpubh.2023.1112981"},{"key":"1436_CR34","unstructured":"Pauldine B. ISMP draws attention to age-related vaccination errors. ECRI and ISMP. 2024, Aug 27. https:\/\/home.ecri.org\/blogs\/ismp-news\/ismp-draws-attention-to-age-related-vaccination-errors?srsltid=AfmBOopY6n6asmGEhL6CxCDEQfRZT2Ed3KBqktCTo9HTDeSqSEPt36ZP. Accessed 2 Jul 2026."},{"issue":"2","key":"1436_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002961","volume":"4","author":"G Joachim","year":"2024","unstructured":"Joachim G, Shih SF, Singh A, et al. Parental vaccine hesitancy and acceptance of a COVID-19 vaccine: an internet-based survey in the US and five Asian countries. PLoS Glob Public Health. 2024;4(2):e0002961.","journal-title":"PLoS Glob Public Health"},{"issue":"9","key":"1436_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009062","volume":"5","author":"DM MacDougall","year":"2015","unstructured":"MacDougall DM, Halperin BA, MacKinnon-Cameron D, et al. The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open. 2015;5(9):e009062.","journal-title":"BMJ Open"},{"issue":"5s","key":"1436_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.59556\/japi.73.0991","volume":"73","author":"S Sathyanarayanan","year":"2025","unstructured":"Sathyanarayanan S, Taur S. Knowledge, attitude, and practice of adult pneumococcal vaccination in India: a prospective, cross-sectional, questionnaire-based survey of pediatricians. J Assoc Physicians India. 2025;73(5s):15\u201320.","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"1436_CR38","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1093\/infdis\/jiaf376","volume":"232","author":"LM King","year":"2025","unstructured":"King LM, Andrejko KL, Kobayashi M, et al. Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines. J Infect Dis. 2025;232(4):e609\u201320.","journal-title":"J Infect Dis"},{"issue":"5","key":"1436_CR39","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/jac\/dkaf085","volume":"80","author":"JJ Schellenberg","year":"2018","unstructured":"Schellenberg JJ, Adam HJ, Baxter MR, et al. Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21. J Antimicrob Chemother. 2018;80(5):1377\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1436_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00175-24","volume":"38","author":"FA Ganaie","year":"2025","unstructured":"Ganaie FA, Beall BW, Yu J, et al. Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward. Clin Microbiol Rev. 2025;38(1):e0017524.","journal-title":"Clin Microbiol Rev"},{"key":"1436_CR41","unstructured":"A profile of physicians in Canada. Canadian Institute for Health Information (CIHI). https:\/\/www.cihi.ca\/en\/a-profile-of-physicians-in-canada. Accessed 7 Jul 2026."},{"key":"1436_CR42","unstructured":"Tran M, Lee JT, Cormack M, Xiang F, Sugiura T, The Australian National University. Health workforce shortage in Australia post COVID-19- International perspectives. In: Health Workforce Data Insights. 2024. https:\/\/nceph.anu.edu.au\/files\/NCHWS%20Data%20Insight%20Serries%20-%20Mar2024.pdf. Accessed 7 Jul 2026."},{"key":"1436_CR43","doi-asserted-by":"crossref","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","DOI":"10.1002\/pds.3891"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01436-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:03:07Z","timestamp":1791864187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01436-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01436-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was sponsored by Pfizer. Jeffrey T Vietri and Sophie A Warren are employees of Pfizer Inc., manufacturer of Prevnar20. Matthew J Heffler is an employee of Ipsos Insight LLC, which was a paid consultant to Pfizer in connection with the development of this manuscript and conducting this research study.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and applicable regulatory and ethical guidelines including the ISPE (International Society for Pharmacoepidemiology) guidelines for Good Pharmacoepidemiology Practices [\n                      \n                      ], and the ISPOR (The Professional Society for Health Economics and Outcomes Research) Good Practices for Outcomes Research. The study was deemed exempt according to 45\u00a0CFR\u00a046.104(d)(2) Tests, Surveys, Interviews 45\u00a0CFR\u00a046.104(d)(3)(i)(A) by Pearl Institutional Review Board (IRB). All participants provided electronic informed consent prior to study participation. No personally identifiable information was collected during the course of the survey, and all analyses were performed on aggregated, de-identified data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}